The real sleeper: SGLT2 inhibitors (a $10/month generic drug class) are now showing telomere elongation — Big Pharma has zero incentive to study this further since the drugs are off-patent, meaning this is likely being quietly buried.
Epigenetic reprogramming (ER-100) is the biotech version of what crypto did to finance — decentralizing "who gets to live longer" from governments to whoever can fund a startup; the first longevity DAOs are already forming around exactly this funding gap.